AU2022485048A1 - Compactable oral formulations of ibutamoren - Google Patents

Compactable oral formulations of ibutamoren Download PDF

Info

Publication number
AU2022485048A1
AU2022485048A1 AU2022485048A AU2022485048A AU2022485048A1 AU 2022485048 A1 AU2022485048 A1 AU 2022485048A1 AU 2022485048 A AU2022485048 A AU 2022485048A AU 2022485048 A AU2022485048 A AU 2022485048A AU 2022485048 A1 AU2022485048 A1 AU 2022485048A1
Authority
AU
Australia
Prior art keywords
day
tablet
solid form
pharmaceutical solid
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022485048A
Other languages
English (en)
Inventor
John C. Mckew
Alpa B. Parikh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lumos Pharma Inc
Original Assignee
Lumos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc filed Critical Lumos Pharma Inc
Publication of AU2022485048A1 publication Critical patent/AU2022485048A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022485048A 2022-11-03 2022-11-22 Compactable oral formulations of ibutamoren Pending AU2022485048A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263422329P 2022-11-03 2022-11-03
US63/422,329 2022-11-03
PCT/US2022/050700 WO2024096892A1 (en) 2022-11-03 2022-11-22 Compactable oral formulations of ibutamoren

Publications (1)

Publication Number Publication Date
AU2022485048A1 true AU2022485048A1 (en) 2025-05-22

Family

ID=90835855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022485048A Pending AU2022485048A1 (en) 2022-11-03 2022-11-22 Compactable oral formulations of ibutamoren

Country Status (12)

Country Link
US (2) US11969416B1 (https=)
EP (1) EP4611737A1 (https=)
JP (2) JP2025535941A (https=)
KR (1) KR20250107210A (https=)
CN (1) CN120239602A (https=)
AU (1) AU2022485048A1 (https=)
CL (1) CL2025001309A1 (https=)
CO (1) CO2025007025A2 (https=)
GE (1) GEAP202516774A (https=)
IL (1) IL320529A (https=)
MX (1) MX2025005154A (https=)
WO (1) WO2024096892A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107210A (ko) 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
AU7522896A (en) 1995-10-27 1997-05-15 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
BR0113626A (pt) * 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
EP2001475B1 (en) 2006-03-15 2018-11-14 Michael O. Thorner Methods for treating sarcopenia with a growth hormone secretagogue
FI20080351A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
WO2014030204A1 (ja) * 2012-08-20 2014-02-27 大日本住友製薬株式会社 薬物含有中空粒子
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
BR112015022398B1 (pt) * 2013-03-14 2022-01-11 Redhill Biopharma Ltd Comprimido de ondansetrona e preparação farmacêutica embalada
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
AU2016328969B2 (en) 2015-09-21 2020-10-08 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
KR20200121308A (ko) * 2018-02-14 2020-10-23 루모스 파마, 인크. 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물
KR20250107210A (ko) 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Also Published As

Publication number Publication date
EP4611737A1 (en) 2025-09-10
JP2025535941A (ja) 2025-10-30
GEAP202516774A (en) 2025-06-25
CL2025001309A1 (es) 2025-09-26
WO2024096892A1 (en) 2024-05-10
CO2025007025A2 (es) 2025-07-17
KR20250107210A (ko) 2025-07-11
JP2026027432A (ja) 2026-02-18
CN120239602A (zh) 2025-07-01
US20240245663A1 (en) 2024-07-25
IL320529A (en) 2025-06-01
MX2025005154A (es) 2025-07-01
US11969416B1 (en) 2024-04-30
US20240156793A1 (en) 2024-05-16
US12390452B2 (en) 2025-08-19

Similar Documents

Publication Publication Date Title
AU2016208417B2 (en) Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate
EP2510950B1 (en) Dry-coated orally disintegrating tablet
US20030108602A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
JP7254871B2 (ja) 口腔内崩壊錠
EP3041476B1 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2014186581A1 (en) Cenicriviroc compositions and methods of making and using the same
WO2011069326A1 (zh) 包含阿替洛尔和氨氯地平的双层片剂
MX2012004903A (es) Composiciones farmaceuticas solidas que contienen un hinibidor de la integrasa.
JP2026027432A (ja) イブタモレンの圧縮型経口製剤
CN111202731A (zh) 联合用药应用以及一种药用组合物及其应用
EP4048276B1 (en) Solid pharmaceutical formulations comprising ticagrelor
EP4667003A2 (en) Bi-layer pharmaceutical tablet formulation
US20050118256A1 (en) Extended release alpha-2 agonist pharmaceutical dosage forms
JP3884056B1 (ja) 口腔内速崩錠の製造方法
WO2022228735A1 (en) Pharmaceutical composition comprising a combination of sitagliptin and metformin and method of preparation thereof
US20250332149A1 (en) Piperidine compounds and pharmaceutical compositions
US20260041641A1 (en) Novel formulation
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
WO2026029720A1 (en) A stable immediate release ticagrelor tablet composition
HK40069975A (en) Solid pharmaceutical compositions containing an integrase inhibitor
TW202317119A (zh) 用於口服投予之分散錠
HK1190064B (en) Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate